Understanding osteomyelitis and its treatment through local drug delivery system

Biotechnol Adv. 2016 Dec;34(8):1305-1317. doi: 10.1016/j.biotechadv.2016.09.005. Epub 2016 Sep 28.

Abstract

Chronic osteomyelitis is a major challenge in bone surgery. Conventional use of antibiotics is not an effective way to control the malaise due to so many reasons. Determination of optimal treatment strategy becomes difficult for the orthopaedic surgeons and as a consequence, the patients suffer not only from therapeutic failure but also due to adverse side effects of antibiotics and financial loss due to additional stay at hospitals. A wide application of carrier systems, as a medium for local delivery of antibiotics, is being used experimentally and clinically for the treatment of osteomyelitis. This kind of delivery system provides sustained higher concentration of antibiotics at the infection site with reduced possibility of toxicity. This review highlight etiology and pathophysiology of osteomyelitis, current therapeutic options with their limitations, and potentiality of biomaterial based carrier materials impregnated with antibiotics as local delivery approach.

Keywords: Biodegradable carriers; Drug release; Local antibiotic delivery system; Non-biodegradable carriers; Osteomyelitis; Pathophysiology.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents* / administration & dosage
  • Anti-Bacterial Agents* / therapeutic use
  • Biocompatible Materials
  • Drug Delivery Systems*
  • Humans
  • Osteomyelitis* / drug therapy
  • Osteomyelitis* / epidemiology
  • Osteomyelitis* / physiopathology
  • Risk Factors

Substances

  • Anti-Bacterial Agents
  • Biocompatible Materials